HomeCompareCHBRF vs ABBV

CHBRF vs ABBV: Dividend Comparison 2026

CHBRF yields 4140.79% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CHBRF wins by $10018711496271.80M in total portfolio value
10 years
CHBRF
CHBRF
● Live price
4140.79%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$10018711496271.90M
Annual income
$9,564,341,159,618,468,000.00
Full CHBRF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CHBRF vs ABBV

📍 CHBRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCHBRFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CHBRF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CHBRF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CHBRF
Annual income on $10K today (after 15% tax)
$351,966.87/yr
After 10yr DRIP, annual income (after tax)
$8,129,689,985,675,697,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CHBRF beats the other by $8,129,689,985,675,676,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CHBRF + ABBV for your $10,000?

CHBRF: 50%ABBV: 50%
100% ABBV50/50100% CHBRF
Portfolio after 10yr
$5009355748136.00M
Annual income
$4,782,170,579,809,246,000.00/yr
Blended yield
95.46%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CHBRF
No analyst data
Altman Z
-21.6
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CHBRF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCHBRFABBV
Forward yield4140.79%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$10018711496271.90M$102.3K
Annual income after 10y$9,564,341,159,618,468,000.00$24,771.77
Total dividends collected$9987759787208.71M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CHBRF vs ABBV ($10,000, DRIP)

YearCHBRF PortfolioCHBRF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$424,779$414,078.67$11,550$430.00+$413.2KCHBRF
2$16,892,998$16,438,485.13$13,472$627.96+$16.88MCHBRF
3$629,048,550$610,973,041.85$15,906$926.08+$629.03MCHBRF
4$21,935,649,065$21,262,567,116.43$19,071$1,382.55+$21935.63MCHBRF
5$716,415,311,987$692,944,167,487.48$23,302$2,095.81+$716415.29MCHBRF
6$21,917,463,606,071$21,150,899,222,244.91$29,150$3,237.93+$21917463.58MCHBRF
7$628,194,188,737,040$604,742,502,678,543.50$37,536$5,121.41+$628194188.70MCHBRF
8$16,871,247,239,066,280$16,199,079,457,117,650.00$50,079$8,338.38+$16871247239.02MCHBRF
9$424,645,174,442,460,860$406,592,939,896,659,900.00$69,753$14,065.80+$424645174442.39MCHBRF
10$10,018,711,496,271,900,000$9,564,341,159,618,468,000.00$102,337$24,771.77+$10018711496271.80MCHBRF

CHBRF vs ABBV: Complete Analysis 2026

CHBRFStock

Chill Brands Group PLC engages in the research and development, production, and sale of cannabidiol consumer products and other lifestyle goods in the United States, the United Kingdom, and rest of Europe. The company offers tobacco alternative products, including smokes and chew pouches. It also provides oral tinctures, soft-gel capsules, massage oils, and topical cosmetic products. The company serves its products under the Chill.com and Zoetic brands. The company was formerly known as Zoetic International Plc and changed its name to Chill Brands Group PLC in August 2021. Chill Brands Group PLC was incorporated in 2014 and is headquartered in London, the United Kingdom.

Full CHBRF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CHBRF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CHBRF vs SCHDCHBRF vs JEPICHBRF vs OCHBRF vs KOCHBRF vs MAINCHBRF vs JNJCHBRF vs MRKCHBRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.